Adenoid cystic carcinoma (ACC) is a rare, insidious malignancy, most commonly originating in the salivary glands, that presents unique diagnostic and therapeutic challenges. Recent decades have seen a ...

“Proton therapy [...] seems to have decisive advantages with regard to the long-term survival of [adenoid cystic carcinoma] [...]” In general, tumors originating from the minor salivary glands often ...

REHOVOT, Israel & WILMINGTON, Del., June 06, 2022 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule ...

Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). This is an ...

In the months leading up to Michael Carnevale’s death from cancer in 2016, he told his wife that he didn’t worry about her and their son, Santino, being taken care of after he was gone. After all, ...

A randomized doubled blind phase II study exploring the safety and efficacy of nintedanib (BIBF1120) as second line therapy for patients (pts) with differentiated thyroid carcinoma (DTC) progressing ...

Pin Therapeutics, a clinical-stage biotechnology company specializing in targeted protein degradation, announced on November 20 that it has administered the first dose of its CK1α-selective degrader ...

WATERTOWN, Mass., Oct. 16, 2024 /PRNewswire/ -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address underlying ...

PIN-5018 achieves complete response in ACC PDX models Expansion planned into mCRPC, colorectal cancer, and other rare tumours ...

- REM-422 granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of ACC and AML - Advances REM-422, an oral small molecule messenger RNA (mRNA) degrader to ...